Global Healthcare Study on Psoriasis

NCT07634016 | Recruiting

• 1 other identifier: 2020-00002
• Study Type: observational
• Target: 9,600
• Locations: 1 country
• Sites: 1

Brief Summary

The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Conditions

Psoriasis (PsO)

Outcome Measures

Primary Outcomes (1)

• Psoriasis Area Severity Index (PASI)

  Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease.

  Baseline and follow-up visits every 6-12 months for up to 5 years.

Secondary Outcomes (5)

• Dermatology Life Quality Index (DLQI)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Nail Psoriasis Severity Index (NAPSI)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Numerical Rating Scale (NRS) for disease severity

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Physician Global Assessment (PGA)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Body Surface Area (BSA)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

Study Arms (1)

Global Healthcare Study on Psoriasis

Patients with Psoriasis

Eligibility Criteria

• Age: 14 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient populations across world regions seen for psoriasis.

You may qualify if:

• Signed General Consent Form, or equivalent document
• Confirmed diagnosis of Psoriasis

You may not qualify if:

• Inability to provide informed consent.
• Datasets with ambiguous or unclear diagnosis.

Sponsors & Collaborators

• Julia Tatjana Maul: lead
• University of Zurich: collaborator
• University Hospital, Zürich: collaborator

Study Sites (1)

University of Zurich

Zurich, Switzerland

RECRUITING

Related Publications (5)

• Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H, Korouri E, Novoa F, Oon HH, Zheng M, Wu JJ, Thyssen JP, Egeberg A, Armstrong AW, Nielsen ML. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta Derm Venereol. 2024 Mar 12;104:adv20329. doi: 10.2340/actadv.v104.20329.

  PMID: 38470165 RESULT

• Valenzuela F, De La Cruz C, Lecaros C, Fernandez J, Hevia G, Maul LV, Thyssen JP, Vera-Kellet C, Egeberg A, Armijo D, Pizarro C, Riveros T, Correa H, Guglielmetti A, Didaskalu JA, Wu JJ, Griffiths CEM, Romiti R, Maul JT. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. Clin Exp Dermatol. 2022 Dec;47(12):2234-2241. doi: 10.1111/ced.15384. Epub 2022 Oct 28.

  PMID: 35988043 RESULT

• Maul JT, Frohlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023 Mar 30;188(4):533-541. doi: 10.1093/bjd/ljac128.

  PMID: 36653920 RESULT

• Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Aguero R, Maul JT, Armstrong AW. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients. Life (Basel). 2024 Oct 13;14(10):1297. doi: 10.3390/life14101297.

  PMID: 39459597 RESULT

• Goh E, Nielsen ML, Maul LV, Didaskalu JA, Chularojanamontri L, Guevara BEK, Ji M, Zheng M, Maul JT, Oon HH. Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP). Int J Dermatol. 2026 Jun;65(6):1195-1202. doi: 10.1111/ijd.70183. Epub 2025 Nov 30.

  PMID: 41319042 RESULT

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Julia-Tatjana Maul, Prof. Dr. med.

  University of Zurich

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Julia-Tatjana Maul

CONTACT

+41 76 441 51 09; julia-tatjana.maul@uzh.ch

Johannes A Didaskalu, Prof. Dr. med.

CONTACT

+41 76 36 19 475; johannes.didaskalu@uzh.ch

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof. Dr. med.

Study Record Dates

• First Submitted: June 2, 2026
• First Posted: June 8, 2026
• Study Start: January 1, 2025
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2029
• Last Updated: June 8, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)